Kensuke Sakuma
Fujisawa, 2518555, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Identification and removal of unexpected proliferative off-target cells emerging after iPSC-derived pancreatic islet cell implantation.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 10, 2024
CDK8/19 inhibition plays an important role in pancreatic β-cell induction from human iPSCs.
Journal: Stem cell research & therapy
Published: July 03, 2022
Characterization and reduction of non-endocrine cells accompanying islet-like endocrine cells differentiated from human iPSC.
Journal: Scientific reports
Published: November 16, 2021
FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia.
Journal: The Journal of pharmacology and experimental therapeutics
Published: May 17, 2017
Effects of 4(1H)-quinolinone derivative, a novel non-nucleotide allosteric purinergic P2Y 2 agonist, on cardiomyocytes in neonatal rats.
Journal: Scientific reports
Published: February 27, 2017
Fasiglifam (TAK-875) has dual potentiating mechanisms via Gαq-GPR40/FFAR1 signaling branches on glucose-dependent insulin secretion.
Journal: Pharmacology research & perspectives
Published: March 22, 2016
Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders.
Journal: PloS one
Published: September 26, 2013
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
Journal: PloS one
Published: June 04, 2013
C. elegans AMPKs promote survival and arrest germline development during nutrient stress.
Journal: Biology open
Published: February 06, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026